Innovative Framework for Value Assessment of Advanced Therapies
Researchers from Analysis Group, a global leader in health economics and outcomes research, have co-developed an insightful framework. This new approach combines findings from clinical trials and real-world evidence (RWE) to evaluate the holistic value of groundbreaking therapies utilized for various medical conditions. The framework, termed the access-focused patient-centric (APAC) framework, encourages formulary decision makers to adopt a comprehensive approach to their utilization management responsibilities. This ensures that patients receive timely and sustained access to necessary treatments.
Addressing the Need for Effective Treatment Evaluation
In recent years, there have been significant advancements in the development of targeted therapies, offering improved treatment alternatives for patients. Notably, therapies for immune-mediated inflammatory diseases have transformed the landscape for managing conditions like psoriasis and rheumatoid arthritis. Given this evolution in healthcare, there is an increasing necessity for an efficient method to inform payers about the holistic value of innovative therapies spanning multiple indications.
Current economic modeling tools employed by formulary decision makers tend to emphasize clinical outcomes based on singular medications affecting individual diseases. While these tools have served their purpose historically, they often overlook a modern understanding of the entire disease experience. Patients suffering from immune-mediated inflammatory diseases face challenges that impact not just their health but also their quality of life, productivity, and relationships with others.
A Comprehensive Collaboration for Change
To propel the understanding of this crucial issue, a team from Analysis Group, led by Managing Principal Min Yang, Manager Qing Liu, and academic affiliate Lou Garrison, collaborated with researchers from AbbVie and various esteemed universities. This collaboration has resulted in the novel APAC methodology, which is outlined in an article published in Advances in Therapy. The authors detail the foundational elements of the framework and illustrate how it can be utilized to assist payers in making informed and timely decisions regarding medication access.
Dr. Yang emphasized the importance of the APAC framework, stating, "This approach promotes evidence-based patient-centricity. By considering both the efficacy of therapies and their impacts on quality of life and productivity from a multi-indication formulary perspective, the APAC framework provides practical and quantifiable information relevant to formulary decision makers."
Facilitating Access to Innovative Treatments
The research team advocates that the APAC framework may serve as a valuable tool for articulating the patient-centric benefits associated with innovative therapies. This method could empower formulary decision makers to ensure the prompt delivery of essential treatments to patients.
Professor Garrison remarked on the challenges posed by formulary decision-making. He noted, "The effective management of resources is crucial. Collaborating with my competent colleagues from Analysis Group, AbbVie, and academia allowed us to confront this complex problem. This refreshed perspective highlights the role of utilization management in tandem with traditional cost-effectiveness analyses. Our aim is to support formulary decision makers in delivering swift and suitable access to treatments, enhancing health outcomes, and promoting equity among patients."
About Analysis Group and Its Expertise
Analysis Group, established in 1981, stands as one of the largest international economics consulting firms, employing over 1,500 professionals across 15 offices worldwide. The firm specializes in health care, applying analytical insights to various areas, including regulatory real-world evidence, health economics, health outcomes research, market access strategies, and drug safety-related engagements in epidemiology. By leveraging its internal expertise alongside a vast network of affiliated experts from academia and industry, Analysis Group delivers comprehensive consulting services globally.
Frequently Asked Questions
What is the APAC framework?
The APAC framework is a new method developed by Analysis Group to assess the holistic value of therapies used for multiple indications, focusing on patient-centric outcomes.
Who contributed to the development of the APAC framework?
The framework was co-developed by a team from Analysis Group, AbbVie, and multiple universities, including key figures like Min Yang and Lou Garrison.
How does the APAC framework benefit formulary decision makers?
It provides practical insights into the efficacy and quality of life impacts of therapies, helping decision makers ensure timely access to innovative treatments.
What are immune-mediated inflammatory diseases (IMIDs)?
IMIDs are conditions where the immune system mistakenly attacks the body's own tissues, leading to chronic inflammation and affecting patients’ quality of life.
What is the mission of Analysis Group in health care?
Analysis Group aims to improve patient outcomes through detailed health economics analysis, providing clients with thorough insights into their healthcare challenges.
